BPH Medical Therapy Options: A High-Yield USMLE Review
Benign prostatic hyperplasia (BPH) is a benign proliferation of prostatic stromal and epithelial cells in the transitional (periurethral) zone that compresses the urethra and produces obstructive and irritative lower urinary tract symptoms. Medical therapy targets two problems: the smooth-muscle tone of the prostate (relieved rapidly with alpha-1 blockers) and the size of the gland itself (reduced slowly with 5-alpha reductase inhibitors). The framework for choosing therapy centers on how bothersome symptoms are, how large the prostate is, and whether irritative symptoms dominate — with surgery reserved for failures and complications.
Alpha-1 Blockers (tamsulosin, alfuzosin, doxazosin)
Alpha-1 blockers relax prostatic smooth muscle, producing rapid symptom improvement within days to weeks. They are first-line for men with moderate-to-bothersome symptoms and are well tolerated. Key side effects to recognize on exams are orthostatic hypotension, retrograde ejaculation, and intraoperative floppy iris syndrome — the last of which is critical to disclose before cataract surgery. Because relief is fast, this is the go-to choice for the man whose main complaint is bothersome symptoms such as frequent nocturia.
5-Alpha Reductase Inhibitors (finasteride, dutasteride)
These agents block conversion of testosterone to DHT, causing the prostate to shrink and reducing prostate size by roughly 20–30%. Improvement is slow, developing over months, so they are not chosen when rapid relief is needed. They are especially useful for larger prostates. Side effects reflect reduced androgen effect: decreased libido, erectile dysfunction, and gynecomastia. A high-yield monitoring point: 5-ARIs lower PSA by about 50%, so you must double the measured PSA when screening for prostate cancer in a man on finasteride or dutasteride.
Combination Therapy (alpha blocker + 5-ARI)
Combining an alpha blocker with a 5-alpha reductase inhibitor pairs rapid symptom relief with progressive gland shrinkage, and is the most effective approach for large prostates. The tradeoff is the combined side-effect profile of both drug classes. A typical exam scenario is the man with bothersome symptoms and a sizeable (e.g., 50 g) prostate: start the alpha blocker for symptom relief and add the 5-ARI for long-term size reduction.
Anticholinergics / Beta-3 Agonists
When irritative (storage) symptoms persist despite treatment, anticholinergics or beta-3 agonists can be added to an alpha blocker to target bladder overactivity. The main caution is urinary retention risk, since reducing detrusor activity in an obstructed outlet can precipitate retention. These are add-on agents, not first-line monotherapy for outlet obstruction.
High-yield
- BPH arises in the transitional (periurethral) zone; enlargement causes obstruction, bladder hypertrophy causes irritative symptoms, and detrusor failure eventually causes retention.
- Severity is graded by the International Prostate Symptom Score (IPSS): mild 0–7, moderate 8–19, severe 20–35.
- Watchful waiting is appropriate for mild, non-bothersome symptoms (IPSS 0–7).
- Alpha-1 blockers = rapid relief; 5-ARIs = slow shrinkage over months.
- 5-ARIs lower PSA by ~50% — double the measured value when monitoring for prostate cancer.
- Floppy iris syndrome is the classic alpha-blocker association relevant to cataract surgery.
- Combination therapy is best for large prostates.
- Surgical indications: refractory retention, recurrent UTIs, renal insufficiency from obstruction, bladder stones, and refractory symptoms despite medical therapy.
Pitfalls
- Choosing finasteride first when the patient needs rapid symptom relief — it works over months, whereas alpha blockers relieve symptoms in days to weeks.
- Forgetting to double the PSA in a man on a 5-ARI, leading to false reassurance and missed prostate cancer.
- Confusing BPH treatment with cancer treatment — radical prostatectomy and TURP are not first-line BPH therapy (TURP is for failed medical therapy or complications).
- Adding anticholinergics/beta-3 agonists without recognizing the urinary retention risk in an obstructed patient.
- Treating asymptomatic or minimally bothersome BPH — mild, non-bothersome symptoms (IPSS 0–7) warrant watchful waiting.
- Overlooking retrograde ejaculation and orthostatic hypotension as expected alpha-blocker effects.
Clinical pearls
- Alpha-blockers for rapid relief; 5-ARIs shrink the prostate over time; surgery for failures and complications.
- BPH is common and benign — match therapy to symptom burden and prostate size.
- Start the alpha blocker for the bothersome man, add the 5-ARI when the prostate is large.
- Any man on finasteride/dutasteride with a 'normal' PSA — double it before you relax.
Frequently asked
Why is an alpha-1 blocker preferred as initial therapy for bothersome BPH symptoms?
Alpha-1 blockers relax prostatic smooth muscle and provide rapid symptom improvement within days to weeks, making them ideal when symptoms (such as nocturia) are bothersome and quick relief is desired. They are also well tolerated.
When would you choose or add a 5-alpha reductase inhibitor?
5-ARIs shrink the prostate by blocking DHT production, reducing prostate size by about 20–30%. They are particularly useful for larger prostates and are typically added to an alpha blocker, with benefit developing slowly over months.
How does finasteride affect PSA monitoring?
5-ARIs lower PSA by approximately 50%. To screen accurately for prostate cancer in a patient on finasteride or dutasteride, you must double the measured PSA value.
What are the characteristic side effects of alpha-1 blockers?
Orthostatic hypotension, retrograde ejaculation, and intraoperative floppy iris syndrome — the latter is important to know before cataract surgery.
Which patients benefit most from combination therapy?
Men with large prostates benefit most from combining an alpha blocker (rapid relief) with a 5-ARI (gland shrinkage), accepting the combined side-effect profile of both classes.
What is the role of anticholinergics or beta-3 agonists in BPH?
They target irritative (storage) symptoms and are added to an alpha blocker when those symptoms persist. The key caution is the risk of urinary retention.
When is medical therapy not needed at all?
Watchful waiting is appropriate for mild, non-bothersome symptoms (IPSS 0–7).
When should you move from medical therapy to surgery?
Surgery is indicated for refractory urinary retention, recurrent UTIs, renal insufficiency from obstruction, bladder stones, or refractory symptoms despite medical therapy.
Turn this into reasoning you can use on exam day — practice BPH Medical Therapy Options on branching cases where your decisions shape the patient.